This “Atrophic Vaginitis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atrophic Vaginitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Vaginal atrophy (also called atrophic vaginitis) is a condition where the lining of the vagina gets drier and thinner. Atrophic vaginitis, a vaginal disorder that usually happens after menopause when estrogen levels fall. Estrogen, which is produced by the ovaries, plays a vital role in keeping vaginal tissues lubricated and healthy. The condition also includes urinary tract problems such as urinary tract infections (UTIs) and frequent urination. Women age 50 and over, in menopause, are the most likely to experience vaginal atrophy. Surgical removal of the ovaries before the age of natural menopause, treatment with medications used to decrease estrogen levels in women who have conditions such as uterine fibroids or endometriosis,breastfeeding are common conditions with low estrogen levels leading to Atrophic Vaginitis.
Dryness of the vagina.
Burning and/or itching of the vagina.
Dyspareunia
A discharge from the vagina - usually a yellow color.
Spotting or bleeding.
Vulvar itching (pruritus).
Painful urination
Atrophic Vaginitis can be diagnosed with careful physical examination of signs and symptoms associated. Occasionally laboratory tests are required to differentiate vaginal atrophy from other conditions such as:Pap test,Urine sample,Ultrasound, Serum hormone testing, Vaginal pH, Microscopy.
Treatments range from over-the-counter moisturizers to prescription-only hormone therapy. The treatment for atrophic vaginitis focuses on increasing estrogen levels and providing symptomatic relief. Vaginal cream, estrogen Replacement Therapy.
This segment of the Atrophic Vaginitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vagitocin:Peptonic Medical
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i. a. the mechanism of action.
DARE-VVA1: Dare Bioscience
DARE-VVA1 is a novel vaginal application of tamoxifen, the well-known and well-characterized selective estrogen receptor modulator (SERM), and is being developed by Daré as an alternative to estrogen-based therapies for the treatment of vulvar and vaginal atrophy (VVA) in women with or at risk for hormone-receptor positive (HR+) breast cancer. In breast tissue, tamoxifen acts as an estrogen antagonist, while in other tissue, including vaginal tissue, tamoxifen has been reported to exert an estrogen-like response on vaginal cytology.
There are approx. 10+ key companies which are developing the therapies for Atrophic Vaginitis. The companies which have their Atrophic Vaginitis drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, Dare Biosciences and others.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrophic Vaginitis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrophic Vaginitis drugs.
Geography Covered
- Global coverage
Atrophic Vaginitis Understanding
Atrophic Vaginitis: Overview
Vaginal atrophy (also called atrophic vaginitis) is a condition where the lining of the vagina gets drier and thinner. Atrophic vaginitis, a vaginal disorder that usually happens after menopause when estrogen levels fall. Estrogen, which is produced by the ovaries, plays a vital role in keeping vaginal tissues lubricated and healthy. The condition also includes urinary tract problems such as urinary tract infections (UTIs) and frequent urination. Women age 50 and over, in menopause, are the most likely to experience vaginal atrophy. Surgical removal of the ovaries before the age of natural menopause, treatment with medications used to decrease estrogen levels in women who have conditions such as uterine fibroids or endometriosis,breastfeeding are common conditions with low estrogen levels leading to Atrophic Vaginitis.
Symptoms
Dryness of the vagina.
Burning and/or itching of the vagina.
Dyspareunia
A discharge from the vagina - usually a yellow color.
Spotting or bleeding.
Vulvar itching (pruritus).
Painful urination
Diagnosis
Atrophic Vaginitis can be diagnosed with careful physical examination of signs and symptoms associated. Occasionally laboratory tests are required to differentiate vaginal atrophy from other conditions such as:Pap test,Urine sample,Ultrasound, Serum hormone testing, Vaginal pH, Microscopy.
Treatment
Treatments range from over-the-counter moisturizers to prescription-only hormone therapy. The treatment for atrophic vaginitis focuses on increasing estrogen levels and providing symptomatic relief. Vaginal cream, estrogen Replacement Therapy.
Atrophic Vaginitis Emerging Drugs Chapters
This segment of the Atrophic Vaginitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atrophic Vaginitis Emerging Drugs
Vagitocin:Peptonic Medical
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i. a. the mechanism of action.
DARE-VVA1: Dare Bioscience
DARE-VVA1 is a novel vaginal application of tamoxifen, the well-known and well-characterized selective estrogen receptor modulator (SERM), and is being developed by Daré as an alternative to estrogen-based therapies for the treatment of vulvar and vaginal atrophy (VVA) in women with or at risk for hormone-receptor positive (HR+) breast cancer. In breast tissue, tamoxifen acts as an estrogen antagonist, while in other tissue, including vaginal tissue, tamoxifen has been reported to exert an estrogen-like response on vaginal cytology.
Atrophic Vaginitis: Therapeutic Assessment
This segment of the report provides insights about the different Atrophic Vaginitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Atrophic Vaginitis
There are approx. 10+ key companies which are developing the therapies for Atrophic Vaginitis. The companies which have their Atrophic Vaginitis drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, Dare Biosciences and others.
Phases
This report covers around 10+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Atrophic Vaginitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intra-Vaginal
- Molecule Type
Products have been categorized under various Molecule types such as
- Gels
- Modulators
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Atrophic Vaginitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrophic Vaginitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrophic Vaginitis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Atrophic Vaginitis R&D. The therapies under development are focused on novel approaches to treat/improve Atrophic Vaginitis.
Atrophic Vaginitis Report Insights
- Atrophic Vaginitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Atrophic Vaginitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atrophic Vaginitis drugs?
- How many Atrophic Vaginitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrophic Vaginitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrophic Vaginitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atrophic Vaginitis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Allergan Plc
- Foamix Pharmaceuticals Ltd
- Mithra Pharmaceuticals SA
- PEPTONIC Medical AB
- Sermonix Pharmaceuticals LLC
Key Products
- DARE-VVA1
- Vagitocin
- Cenestin
- TX-004HR
Table of Contents
IntroductionExecutive Summary
Atrophic Vaginitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Atrophic Vaginitis - Analytical Perspective
In-depth Commercial Assessment
- Atrophic Vaginitis companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Atrophic Vaginitis Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
- Comparative Analysis
Vagitocin:Peptonic Medical
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
DARE-VVA1: Dare Bioscience
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Atrophic Vaginitis Key Companies
Atrophic Vaginitis Key Products
Atrophic Vaginitis- Unmet Needs
Atrophic Vaginitis- Market Drivers and Barriers
Atrophic Vaginitis- Future Perspectives and Conclusion
Atrophic Vaginitis Analyst Views
Atrophic Vaginitis Key Companies
AppendixList of Tables
Table 1 Total Products for Atrophic Vaginitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Atrophic Vaginitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allergan Plc
- Foamix Pharmaceuticals Ltd
- Mithra Pharmaceuticals SA
- PEPTONIC Medical AB
- Sermonix Pharmaceuticals LLC
